Aberrant methylation of DLC-1 promoter in retinoblastoma

ZHOU Dan-qiu,MA Wei-zhe,ZHANG Xin-ju,KANG Zhi-hua,GUAN Ming,KE Bi-lian
DOI: https://doi.org/10.13602/j.cnki.jcls.2013.05.022
2013-01-01
Abstract:Objective To investigate the methylation status of DLC-1 in retinoblastoma(RB) tissue and its correlation with clinical parameters.Methods Thirty-seven paraffin-embedded RB tissue samples,4 normal eye tissue samples and 2 retinoblastoma cell line(Y79 and WERI-Rb1) samples were collected,and their methylation status of DLC-1 were quantitatively detected with the methylation-sensitive high resolution melting(MS-HRM) method.Then,the bisulfite genomic sequencing was used to validate the methylation status of DLC-1 gene.In the meanwhile,the expression of DLC-1 mRNA in Y79 and WERI-Rb1 cell lines were determined by RT-PCR.Results Aberrant DLC-1 methylation was detected in 13(35.1%) of 37 RB samples,but was not found in normal eye tissues.DLC-1 mRNA was detected in Y79 and WERI-Rb1 cell lines.The DLC-1 methylation was not correlated with tumor differentiation,other accompanied cancers and family history.However,the methylation rate of DLC-1 promoter in unilateral RB patients was significantly higher than that in bilateral patients(P<0.05).Conclusion Aberrant methylation of DLC-1 promoter exists in RB patients,and may play a role in the pathogenesis of RB.
What problem does this paper attempt to address?